SCHEMBL3585938

SCHEMBL3585938

CCCCC(O)c1[c]cccc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.40
KDM4E B2RXH2 1/20 0.40
LMNA P02545 1/20 0.35
CSNK1E P49674 1/20 0.35
CNR2 P34972 1/20 0.35
CA2 P00918 2/20 0.34
POLB P06746 1/20 0.34
CYP3A4 P08684 1/20 0.34
ASAH1 Q13510 1/20 0.33
MEN1 O00255 1/20 0.32
MAPT P10636 1/20 0.32
MAPK1 P28482 1/20 0.32
KMT2A Q03164 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
CA1 P00915 1/20 0.32
CA4 P22748 1/20 0.32
CA7 P43166 1/20 0.32
CA9 Q16790 1/20 0.32
AOC3 Q16853 1/20 0.32
PCSK9 Q8NBP7 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1145324 0.95 CSNK1E (0.41) ALDH1A1KDM4ELMNACSNK1ECNR2
SCHEMBL3594352 0.93 CSNK1E (0.43) ALDH1A1CSNK1ECNR2ASAH1
SCHEMBL3582718 0.93 CSNK1E (0.43) ALDH1A1CSNK1ECNR2ASAH1
SCHEMBL3587334 0.93 CSNK1E (0.43) ALDH1A1CSNK1ECNR2ASAH1
SCHEMBL3594986 0.93 CSNK1E (0.43) ALDH1A1CSNK1ECNR2ASAH1
SCHEMBL3584428 0.93 CSNK1E (0.43) ALDH1A1CSNK1ECNR2ASAH1
SCHEMBL3589049 0.93 CSNK1E (0.43) ALDH1A1CSNK1ECNR2ASAH1
SCHEMBL3590952 0.93 CSNK1E (0.43) ALDH1A1CSNK1ECNR2ASAH1
SCHEMBL158756 0.91 LMNA (0.36) ALDH1A1KDM4ELMNAPOLBAOC3
SCHEMBL817103 0.83 CNR2 (0.33) ALDH1A1KDM4ECNR2CA2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7741242-B2 Prepared by crosslinking a homogenized an addition polymer containing units from an unsaturated aryl-containing glycidyl ether or ester and an unsaturated alcohol or carboxylic acid and a zero-valent Pd compound to physically deposit the Pd compound on the polymer; oxidizing alcohols to aldehydes WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) 2010-06-22 US disclosed
EP-1537913-B1 PALLADIUM CATALYST COMPOSITION WAKO PURE CHEMICAL INDUSTIES L (JP) 2009-07-01 EP disclosed
US-20060019822-A1 Palladium catalyst composition JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) 2006-01-26 US disclosed
EP-1537913-A1 PALLADIUM CATALYST COMPOSITION Wako Pure Chemical Industies, Ltd. (JP) 2005-06-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060019822-A1 Palladium catalyst composition ODC1, NUDC, ADH1C ALDH1A1 244/4885KDM4E 3507/4885LMNA 3521/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.